18.207.129.175
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Oculoplastics
Thyroid Eye Disease

Teprotumumab study finds mixed response rates for active thyroid eye disease

Posted on

Teprotumumab therapy for active thyroid eye disease demonstrates variable response rates and limited long-term improvement, based on data from a retrospective case series.

While 33% of patients maintained a response 2 years after treatment, the study reveals that proptosis and clinical activity score (CAS) regression often occur in the context of disease reactivation in a significant portion of cases (80%). In addition, teprotumumab treatment appears to offer minimal long-term improvement in diplopia.

The cohort comprised 21 patients, and the primary outcome measure was reactivation, defined as a regression in proptosis (≥2mm increase in either eye, returning within ≤2mm of pre-treatment levels) and CAS worsening by ≥2 points. The secondary outcome assessed diplopia response.

Results showed that the average long-term improvement in proptosis in the eye with more proptosis after teprotumumab was 1.57mm (range, -3-4 mm). Of the initial responders (17 out of 21 patients), 47% experienced reactivations, while 12% had isolated proptosis regressions. Overall, only 33% of patients demonstrated continued response throughout the 2-year study period. The average time to regression was 12.25 months (range, 2-22.5 months).

There was no statistically significant change in diplopia at the final visit in any subgroup, suggesting teprotumumab treatment offers minimal long-term improvement in diplopia.

Reference
Hwang CJ, Rebollo NP, Mechels KB, Perry JD. Reactivation after teprotumumab treatment for active thyroid eye disease. Am J Ophthalmol. 2023;S0002-9394(23)00504-4. doi: 10.1016/j.ajo.2023.12.001. Epub ahead of print. PMID: 38142982.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-